Eugia Pharma Receives USFDA Approval for Olanzapine for Injection 10 mg Single-Dose Vials
Published: October 22, 2020
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olanzapine for Injection, 10 mg/vial, Single-dose Vials.
Indications for this product include:
- Acute agitation associated with schizophrenia and bipolar I mania.
Refer to package insert for full prescribing information including Boxed Warning.